Background
The upper (URT) and lower (LRT) respiratory tracts are the principal sites of SARS-CoV-2 infection and severe COVID-19 disease, respectively. While serum anti-Spike antibody levels are associated with a reduced risk of reinfection, the mechanistic correlates of airway protection remain unclear.
Methods
In this prospective cohort study, we recruited HIV-uninfected, COVID-19–unvaccinated adults in Blantyre, Malawi. Bronchoalveolar lavage (BAL), nasosorption, and peripheral blood samples were collected. Antibody responses were quantified using Meso Scale Discovery immunoassays, and SARS-CoV-2–specific T cell responses were assessed by intracellular cytokine staining (ICS). Group comparisons were evaluated using the Wilcoxon rank-sum test, and correlations were analyzed with Spearman’s rank test.
Results
All 43 participants (M =23; F =20) had detectable serum anti–wildtype (wt) Nucleocapsid (N) and Spike (S) IgG, indicating prior exposure. Anti-S and -N IgG and IgA were detected across serum, URT, and LRT compartments. Serum strongly correlated with LRT anti-wt S (r=0.598, p<0.0001) and N (r=0.637, p<0.0001) IgG, but correlations with URT IgG were weaker (S: r=0.46, p=0.02; N: r=0.194, p=0.333). Frequencies of wt S- and N-specific CD4⁺ were significantly higher in the LRT than in the blood (all p<0.05), with no correlation between compartments.
Conclusions
Serum anti-S IgG correlates more strongly with LRT than URT antibodies in adults with prior SARS-CoV-2 exposure, supporting its use as a surrogate marker of protection against lower airway disease rather than upper airway infection.